Cellenkos' ALS Therapy CK0803 Granted FDA Fast Track Status

The FDA has given Fast Track designation to CK0803, an investigational T-regulatory cell therapy for Amyotrophic Lateral Sclerosis (ALS). This status aims to accelerate development and review for serious conditions with unmet medical needs. Previous Phase 1b data indicated stabilization of ALSFRS-R decline, offering potential hope for patients.